HK1258092A1 - 新表位的迭代發現及其適應性免疫療法和方法 - Google Patents
新表位的迭代發現及其適應性免疫療法和方法Info
- Publication number
- HK1258092A1 HK1258092A1 HK19100476.2A HK19100476A HK1258092A1 HK 1258092 A1 HK1258092 A1 HK 1258092A1 HK 19100476 A HK19100476 A HK 19100476A HK 1258092 A1 HK1258092 A1 HK 1258092A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- neoepitopes
- methods therefor
- adaptive immunotherapy
- iterative discovery
- iterative
- Prior art date
Links
- 230000003044 adaptive effect Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Primary Health Care (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562240482P | 2015-10-12 | 2015-10-12 | |
PCT/US2016/056668 WO2017066339A1 (en) | 2015-10-12 | 2016-10-12 | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1258092A1 true HK1258092A1 (zh) | 2019-11-01 |
Family
ID=57886467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19100476.2A HK1258092A1 (zh) | 2015-10-12 | 2019-01-11 | 新表位的迭代發現及其適應性免疫療法和方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US10532089B2 (zh) |
EP (2) | EP3362797A4 (zh) |
JP (2) | JP2018535202A (zh) |
KR (2) | KR20180087246A (zh) |
CN (1) | CN108700592B (zh) |
AU (1) | AU2016339022B2 (zh) |
CA (1) | CA3003305A1 (zh) |
HK (1) | HK1258092A1 (zh) |
IL (1) | IL258681B2 (zh) |
MX (1) | MX2018004541A (zh) |
WO (1) | WO2017066339A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016339022B2 (en) | 2015-10-12 | 2020-09-10 | Nantomics, Llc | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor |
TW201739919A (zh) * | 2016-02-12 | 2017-11-16 | 南坦生物組學有限責任公司 | 患者特異性新抗原決定基之高通量識別以作為用於癌症免疫療法之治療劑 |
US10534746B2 (en) * | 2016-05-09 | 2020-01-14 | Droplit, Inc. | System and method for defining machine-to-machine communicating devices and defining and distributing computational tasks among same |
RS62390B1 (sr) * | 2016-07-20 | 2021-10-29 | BioNTech SE | Izbor neoepitopa kao ciljeva specifičnih za bolest za terapiju sa povećanom efikasnošću |
US20210113672A1 (en) * | 2016-12-08 | 2021-04-22 | Nantbio, Inc. | Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells |
EP3933408A1 (en) * | 2017-05-30 | 2022-01-05 | Nant Holdings IP LLC | Circulating tumor cell enrichment using neoepitopes |
EP3688165A4 (en) * | 2017-09-25 | 2021-09-29 | Nant Holdings IP, LLC | NEO-EPITOPE PRESENTATION VALIDATION |
US20210172961A1 (en) * | 2018-07-27 | 2021-06-10 | Board Of Regents, The University Of Texas System | Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer |
CN110211633B (zh) * | 2019-05-06 | 2021-08-31 | 臻和精准医学检验实验室无锡有限公司 | Mgmt基因启动子甲基化的检测方法、测序数据的处理方法及处理装置 |
CN110893236A (zh) * | 2019-10-09 | 2020-03-20 | 中山大学 | 溶酶体靶向的抗体药物偶联物及其应用 |
CN111951884B (zh) * | 2020-07-10 | 2022-03-22 | 中南大学 | 蛋白质小分子结合口袋上关键柔性氨基酸的识别方法 |
WO2022047242A2 (en) * | 2020-08-28 | 2022-03-03 | Envisagenics, Inc. | Neoantigens, methods and detection of use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2518569C (en) | 2003-03-10 | 2011-11-15 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
CN100406061C (zh) * | 2005-03-14 | 2008-07-30 | 博尔诚(北京)科技有限公司 | 调节性t细胞耗损剂在制备药物中的用途 |
DK2564340T3 (da) | 2010-04-29 | 2020-02-10 | Univ California | Stigenkendelsesalgoritme ved anvendelse af dataintegration i genommodeller (paradigme) |
US10192641B2 (en) | 2010-04-29 | 2019-01-29 | The Regents Of The University Of California | Method of generating a dynamic pathway map |
US9115402B2 (en) * | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
KR101952965B1 (ko) | 2010-05-25 | 2019-02-27 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Bambam:고처리율 서열분석 데이터의 병렬 비교 분석 |
EP2776959B1 (en) * | 2011-11-11 | 2021-08-11 | Robert Beckman | Personalized strategic cancer treatment |
EP2901341B1 (en) | 2012-09-28 | 2019-04-10 | The University of Connecticut | Identification of tumor-protective epitopes for the treatment of cancers |
EP2903731A1 (en) | 2012-10-08 | 2015-08-12 | Shell Internationale Research Maatschappij B.V. | Biomass conversion systems and methods for use thereof |
WO2014058987A1 (en) | 2012-10-09 | 2014-04-17 | Five3 Genomics, Llc | Systems and methods for tumor clonality analysis |
CA2892391C (en) * | 2012-11-28 | 2023-10-17 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
KR102341899B1 (ko) | 2013-04-07 | 2021-12-21 | 더 브로드 인스티튜트, 인코퍼레이티드 | 개인맞춤화 신생물 백신을 위한 조성물 및 방법 |
JP2017502983A (ja) * | 2013-10-02 | 2017-01-26 | スリ テクノロジーズ エルティーディー. | 不均一な腫瘍を処置するための患者特異的免疫療法 |
JP7060324B2 (ja) * | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
WO2015118529A1 (en) | 2014-02-04 | 2015-08-13 | Optimata Ltd. | Method and system for prediction of medical treatment effect |
WO2015164560A1 (en) | 2014-04-25 | 2015-10-29 | Diatech Oncology, Llc | Intertumoral homogeneity determined by mick assay |
RU2018106934A (ru) | 2015-08-25 | 2019-09-26 | Нантомикс, Ллс | Системы и способы высокоточного определения вариантов |
AU2016339022B2 (en) | 2015-10-12 | 2020-09-10 | Nantomics, Llc | Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor |
MA43124A (fr) | 2015-10-14 | 2018-09-05 | Advaxis Inc | Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse |
-
2016
- 2016-10-12 AU AU2016339022A patent/AU2016339022B2/en active Active
- 2016-10-12 EP EP16856122.3A patent/EP3362797A4/en active Pending
- 2016-10-12 WO PCT/US2016/056668 patent/WO2017066339A1/en active Application Filing
- 2016-10-12 EP EP21163389.6A patent/EP3855444A1/en active Pending
- 2016-10-12 MX MX2018004541A patent/MX2018004541A/es unknown
- 2016-10-12 KR KR1020187013140A patent/KR20180087246A/ko not_active Application Discontinuation
- 2016-10-12 CA CA3003305A patent/CA3003305A1/en active Pending
- 2016-10-12 US US15/291,911 patent/US10532089B2/en active Active
- 2016-10-12 JP JP2018519040A patent/JP2018535202A/ja active Pending
- 2016-10-12 CN CN201680072233.XA patent/CN108700592B/zh active Active
- 2016-10-12 KR KR1020247000744A patent/KR20240010089A/ko not_active Application Discontinuation
-
2018
- 2018-04-12 IL IL258681A patent/IL258681B2/en unknown
-
2019
- 2019-01-11 HK HK19100476.2A patent/HK1258092A1/zh unknown
- 2019-12-13 US US16/713,680 patent/US11717564B2/en active Active
-
2021
- 2021-08-06 JP JP2021129793A patent/JP2021178865A/ja active Pending
-
2023
- 2023-05-22 US US18/321,635 patent/US20230293651A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL258681A (en) | 2018-06-28 |
KR20240010089A (ko) | 2024-01-23 |
CN108700592B (zh) | 2021-08-24 |
IL258681B2 (en) | 2023-05-01 |
JP2021178865A (ja) | 2021-11-18 |
US20230293651A1 (en) | 2023-09-21 |
WO2017066339A4 (en) | 2017-06-22 |
US20200113985A1 (en) | 2020-04-16 |
EP3362797A4 (en) | 2019-06-19 |
WO2017066339A1 (en) | 2017-04-20 |
AU2016339022A1 (en) | 2018-05-10 |
US20170028043A1 (en) | 2017-02-02 |
KR20180087246A (ko) | 2018-08-01 |
CA3003305A1 (en) | 2017-04-20 |
US10532089B2 (en) | 2020-01-14 |
JP2018535202A (ja) | 2018-11-29 |
EP3362797A1 (en) | 2018-08-22 |
IL258681B1 (en) | 2023-01-01 |
CN108700592A (zh) | 2018-10-23 |
US11717564B2 (en) | 2023-08-08 |
EP3855444A1 (en) | 2021-07-28 |
AU2016339022B2 (en) | 2020-09-10 |
MX2018004541A (es) | 2019-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258092A1 (zh) | 新表位的迭代發現及其適應性免疫療法和方法 | |
HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
HRP20181359T1 (hr) | Anti-jagged1 protutijela i postupci uporabe | |
IL251868B (en) | Anti-tim3 antibodies and methods of use | |
EP3245291A4 (en) | Novel micro-dystrophins and related methods of use | |
EP3233921A4 (en) | Anti-c5 antibodies and methods of use | |
EP3177322A4 (en) | Anti-trem2 antibodies and methods of use thereof | |
EP3125960A4 (en) | Click-crosslinked hydrogels and methods of use | |
IL251165A0 (en) | Anti-il-1beta antibodies and methods of their use | |
EP3116911B8 (en) | Anti-mcam antibodies and associated methods of use | |
EP3218005A4 (en) | Glycan-interacting compounds and methods of use | |
EP3134121A4 (en) | Novel anti-rnf43 antibodies and methods of use | |
EP3189079A4 (en) | Novel anti-mfi2 antibodies and methods of use | |
EP3389705A4 (en) | IMMERSOPERAPY BASED ON LISTERIA AND METHODS OF USE | |
EP3099493A4 (en) | Printbars and methods of forming printbars | |
IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
SG10202007893TA (en) | Methods of immunotherapy | |
EP3324959C0 (en) | LICOFELON DERIVATIVES AND METHODS OF USE |